SCHEMBL793097

SCHEMBL793097

Cn1ccc2ccc(S(=O)(=O)Cl)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.50
PKM P14618 2/20 0.40
PKLR P30613 1/20 0.38
PRKCI P41743 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PER2 O15055 1/20 0.36
CRY1 Q16526 1/20 0.36
CRY2 Q49AN0 1/20 0.36
HTR6 P50406 4/20 0.35
PIK3CB P42338 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SIRT6 Q8N6T7 1/20 0.34
CFTR P13569 1/20 0.34
THRB P10828 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL516947 0.86 PKM (0.54) CYP2A6PKMPKLRPRKCISIRT6
SCHEMBL2177417 0.84 CYP2A6 (0.51) CYP2A6PKMPKLRPRKCIL3MBTL1
SCHEMBL517089 0.82 CYP2A6 (0.50) CYP2A6PKMPRKCIPIK3CBALDH1A1
SCHEMBL22951479 0.79 CYP2A6 (0.47) CYP2A6PKMPKLRPRKCIL3MBTL1
SCHEMBL8259764 0.76 HTR6 (0.40) PKML3MBTL1HTR6MEN1KMT2A
SCHEMBL14896280 0.75 OXER1 (0.40) L3MBTL1HTR6MEN1KMT2AALDH1A1
SCHEMBL30329138 0.74 ALDH1A1 (0.32) HTR6MEN1KMT2AALDH1A1HSD17B10
SCHEMBL31142624 0.73 HTR6 (0.31) HTR6ALDH1A1HSD17B10TDP1
SCHEMBL25248942 0.72 NAMPT (0.43) ALDH1A1HSD17B10TDP1
SCHEMBL13131546 0.72 PKM (0.51) CYP2A6PKMPKLRPRKCISIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240285614-A1 PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-08-29 US disclosed
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 US disclosed
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 US disclosed
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 US disclosed
US-9120767-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z.O.O. (PL) 2015-09-01 US disclosed
US-9079902-B2 Heteroaryl sodium channel inhibitors AMGEN INC. (US) 2015-07-14 US disclosed
US-9079902-B2 Heteroaryl sodium channel inhibitors AMGEN INC. (US) 2015-07-14 US disclosed
US-8193180-B2 N-amino tetrahydrothiazine derivatives, method of manufacture and use WOMEN & INFANTS HOSPITAL (US) 2012-06-05 US disclosed
US-8193180-B2 N-amino tetrahydrothiazine derivatives, method of manufacture and use WOMEN & INFANTS HOSPITAL (US) 2012-06-05 US disclosed
US-8193180-B2 N-amino tetrahydrothiazine derivatives, method of manufacture and use WOMEN & INFANTS HOSPITAL (US) 2012-06-05 US disclosed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO disclosed
US-20100179136-A1 N-AMINO TETRAHYDROTHIAZINE DERIVATIVES, METHOD OF MANUFACTURE AND USE WOMEN & INFANTS HOSPITAL (US) 2010-07-15 US disclosed
US-20100179136-A1 N-AMINO TETRAHYDROTHIAZINE DERIVATIVES, METHOD OF MANUFACTURE AND USE WOMEN & INFANTS HOSPITAL (US) 2010-07-15 US disclosed
US-20100179136-A1 N-AMINO TETRAHYDROTHIAZINE DERIVATIVES, METHOD OF MANUFACTURE AND USE WOMEN & INFANTS HOSPITAL (US) 2010-07-15 US disclosed
EP-2114410-A2 N-AMINO TETRAHYDROTHIAZINE DERIVATIVES, METHOD OF MANUFACTURE AND USE Woman & Infants Hospital (US) 2009-11-11 EP disclosed
WO-2008091946-A2 N-AMINO TETRAHYDROTHIAZINE DERIVATIVES, METHOD OF MANUFACTURE AND USE WOMEN & INFANTS HOSPITAL (US) 2008-07-31 WO disclosed
WO-2008091946-A2 N-AMINO TETRAHYDROTHIAZINE DERIVATIVES, METHOD OF MANUFACTURE AND USE WOMEN & INFANTS HOSPITAL (US) 2008-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240285614-A1 PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF RRM2B, RRM2, RRM1 CYP2A6 2404/4885PKM 3249/4885PKLR 1310/4885
US-20100179136-A1 N-AMINO TETRAHYDROTHIAZINE DERIVATIVES, METHOD OF MANUFACTURE AND USE NNMT, GNMT, BHMT2 CYP2A6 3259/4885PKM 3072/4885PKLR 4069/4885
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors SCN7A, SCN1A, SCN5A CYP2A6 1100/4885PKM 3642/4885PKLR 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.